 Home > Active Ingredient News > Antitumor Therapy > AstraZenecon's EGFR inhibitor osimertinib assists in the treatment of non-small cell lung cancer and is given FDA priority review.

AstraZenecon's EGFR inhibitor osimertinib assists in the treatment of non-small cell lung cancer and is given FDA priority review.

 Last Update: 2020-10-28
 Source: Internet
 Author: User

Tags

new orlando

new route

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

AstraZeneca's EGFR tyrosine kinase inhibitor Tagrisso (osimertinib) has been given priority review by the U.S. Food and Drug Administration (FDA) for complementary treatment in patients with early (Ib, II, IIIA) non-small cell lung cancer (NSCLC) mutations after surgical removal.
AZ's Application for Complementary New Drugs (SNDA) for Tagrisso is based on the results of the ADAURA Phase III clinical trial, which showed statistically and clinically significant improvements in disease-free survival (DFS) in patients with EGFR mutations after Tagrisso's treatment.
that although 30% of NSCLC patients can have surgical removal due to an earlier diagnosis, recurrence is still common.
half and more than three-quarters of patients with Phase II and Phase II NSCLC had cancer recurrence within five years, respectively. Dave Fredrickson, executive vice president of
's Oncology division, said: "EGFR mutant lung cancer patients still have a considerable risk of recurrence after surgery and complementary chemotherapy, and new targeted treatments are critical to improving outcomes for these patients.
"

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.